News Article

Deal or no deal?

In 2023, the answer was often ‘deal’!

Over US$ 84 billion worth of deals were closed in the global pharmaceutical industry last year, and it is interesting to note that some key themes and driving factors emerge when you examine these transactions more closely.

There is no one-size-fits-all approach.

M&A can be as much about a company’s philosophy as it is about rational commercial decision-making. Is this a good thing? Candesic’s Managing Partner Dr Leonid Shapiro and Principal Dr Joe Taylor share their thoughts on the market in this PharmaTimes Media Ltd piece.